Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) is a publicly traded, late-stage biopharmaceutical company, leading the development of targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies.
Actinium's lead product candidate, Iomab-B, is licensed from the Fred Hutchinson Cancer Research Center and is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Our drug development pipeline features Iomab-B with positive pivotal Phase 3 SIERRA trial results. We believe Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates.
Actinium is also developing Actimab-A, our lead alpha particle drug candidate, which is being studied under the NCI CRADA and developed in combination with other regimens in AML to leverage its mutation-agnostic, resistant mechanism of action. Actinium is focused on continuing to expand its drug development pipeline of targeted radiotherapies for patients with blood cancers and solid tumors.
Actinium Pharmaceuticals is based in New York, NY.